GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

China Resources Pharmaceutical Group 3320.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

4.67

0.00%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥349.37bn

FY2016FY2025

Net income

CN¥5.24bn

FY2016FY2025

Free cash flow

CN¥21.93bn

FY2016FY2025

Shareholders' equity

CN¥66.68bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥349.37bnCN¥274.18bnCN¥270.40bnCN¥223.13bnCN¥193.24bnCN¥168.63bnCN¥180.08bnCN¥158.75bnCN¥145.55bnCN¥140.36bn
Gross profitCN¥57.68bnCN¥43.30bnCN¥42.43bnCN¥34.36bnCN¥28.87bnCN¥27.17bnCN¥29.96bnCN¥29.23bnCN¥23.85bnCN¥21.59bn
Research and developmentCN¥3.67bnCN¥2.47bnCN¥2.73bnCN¥1.83bnCN¥1.38bnCN¥1.11bnCN¥1.02bnCN¥890.8mCN¥766.2mCN¥707.1m
Operating incomeCN¥16.19bnCN¥12.56bnCN¥13.90bnCN¥9.49bnCN¥7.55bnCN¥7.13bnCN¥7.07bnCN¥9.00bnCN¥7.78bnCN¥7.60bn
Net incomeCN¥5.24bnCN¥3.57bnCN¥4.24bnCN¥3.64bnCN¥3.08bnCN¥2.77bnCN¥2.89bnCN¥3.49bnCN¥2.94bnCN¥2.53bn
Diluted earnings per share0.830.570.670.580.490.440.460.560.470.49

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥370.71bnCN¥319.40bnCN¥316.14bnCN¥249.43bnCN¥236.20bnCN¥209.37bnCN¥190.03bnCN¥147.44bnCN¥135.62bnCN¥120.01bn
Cash and short-term investmentsCN¥36.16bnCN¥31.77bnCN¥41.29bnCN¥33.26bnCN¥35.46bnCN¥45.85bnCN¥38.93bnCN¥37.37bnCN¥20.72bnCN¥18.17bn
Total liabilitiesCN¥218.36bnCN¥197.85bnCN¥197.03bnCN¥156.20bnCN¥146.22bnCN¥129.34bnCN¥120.44bnCN¥96.84bnCN¥82.35bnCN¥71.37bn
DebtCN¥119.77bnCN¥69.01bnCN¥65.15bnCN¥56.42bnCN¥50.96bnCN¥44.16bnCN¥41.27bnCN¥50.94bnCN¥36.88bnCN¥25.71bn
Shareholders' equityCN¥66.68bnCN¥59.78bnCN¥58.93bnCN¥50.68bnCN¥48.45bnCN¥46.47bnCN¥40.71bnCN¥32.90bnCN¥35.32bnCN¥33.70bn
Shares outstanding6,283m6,283m6,283m6,283m6,283m6,283m6,285m6,285m6,285m5,196m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥26.53bnCN¥18.65bnCN¥18.11bnCN¥11.14bnCN¥10.66bnCN¥5.28bnCN¥4.63bnCN¥6.90bnCN¥4.10bnCN¥3.69bn
Capital spending−CN¥4.60bn−CN¥3.00bn−CN¥3.65bn−CN¥3.43bn−CN¥2.76bn−CN¥1.87bn−CN¥1.80bn−CN¥1.27bn−CN¥1.32bn−CN¥1.54bn
Free cash flowCN¥21.93bnCN¥15.65bnCN¥14.46bnCN¥7.71bnCN¥7.90bnCN¥3.41bnCN¥2.83bnCN¥5.63bnCN¥2.78bnCN¥2.15bn
Dividends paid−CN¥1.01bn−CN¥1.61bn−CN¥1.13bn−CN¥963.6m−CN¥716.4m−CN¥581.4m−CN¥719.6m−CN¥578.5m−CN¥477.2m−CN¥565.6m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
RevenueCN¥178.50bnCN¥178.47bnCN¥168.27bnCN¥137.35bnCN¥139.35bnCN¥134.09bnCN¥128.37bnCN¥112.74bn
Gross profitCN¥28.59bnCN¥29.81bnCN¥27.45bnCN¥21.02bnCN¥22.68bnCN¥20.44bnCN¥20.64bnCN¥16.95bn
Operating incomeCN¥8.35bnCN¥6.67bnCN¥9.37bnCN¥4.84bnCN¥7.72bnCN¥4.14bnCN¥6.50bnCN¥3.68bn
Net incomeCN¥2.90bnCN¥2.55bnCN¥2.65bnCN¥793.9mCN¥2.82bnCN¥1.21bnCN¥2.81bnCN¥985.5m
Diluted earnings per share0.460.410.420.130.450.190.450.16
Cash from operations—CN¥23.44bnCN¥1.08bnCN¥19.47bn−CN¥1.91bnCN¥24.91bn−CN¥5.92bnCN¥13.41bn
Capital spending—−CN¥1.36bn−CN¥1.64bn−CN¥1.86bn−CN¥1.14bn−CN¥1.75bn−CN¥1.52bn−CN¥1.52bn
Free cash flow—CN¥22.08bn−CN¥556.0mCN¥17.61bn−CN¥3.05bnCN¥23.16bn−CN¥7.44bnCN¥11.89bn
Total assetsCN¥396.11bnCN¥370.71bnCN¥366.03bnCN¥274.28bnCN¥286.20bnCN¥246.77bnCN¥252.00bnCN¥211.87bn
Cash and short-term investmentsCN¥51.27bnCN¥36.16bnCN¥40.22bnCN¥27.28bnCN¥41.67bnCN¥59.27bnCN¥36.08bnCN¥28.56bn
DebtCN¥100.76bnCN¥119.77bnCN¥102.99bnCN¥71.88bnCN¥96.15bnCN¥62.16bnCN¥85.27bnCN¥60.60bn
Shareholders' equityCN¥71.06bnCN¥66.68bnCN¥63.76bnCN¥51.34bnCN¥51.97bnCN¥45.96bnCN¥46.58bnCN¥43.52bn

Financial ratios

Data as of 23 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin16.5%15.8%15.7%15.4%14.9%16.1%
Operating margin4.6%4.6%5.1%4.3%3.9%4.2%
Net margin1.5%1.3%1.6%1.6%1.6%1.6%
Return on equity7.9%6.9%8.4%8.4%7.4%6.0%
Return on assets1.4%1.3%1.6%1.7%1.5%1.3%
Free cash flow yield97.7%79.1%68.3%45.7%42.1%26.1%
Revenue growth9.4%1.4%21.2%15.5%14.6%-6.4%
Earnings growth26.3%-15.9%16.4%18.4%10.9%-4.2%
Current ratio1.42x1.41x1.46x1.26x1.25x1.20x
Debt to equity1.78x1.39x1.21x1.30x1.35x0.91x
Equity ratio18.0%18.7%18.6%20.3%20.5%22.2%
Interest coverage6.33x5.51x5.83x3.79x3.41x2.69x
R&D as a share of sales1.1%0.9%1.0%0.8%0.7%0.7%
Buybacks as a share of market value0.0%0.0%0.0%0.0%0.0%0.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue16.1%15.7%11.0%
Operating income19.5%17.8%8.6%
Net income12.9%13.6%8.2%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin16.2%15.9%15.8%16.1%
Operating margin4.6%4.7%4.5%4.7%
Net margin1.4%1.5%1.5%1.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings4.89.47.610.97.39.015.718.421.618.0
Price to sales0.10.10.10.20.10.10.30.40.40.3

Dividends and splits

Per share, in the currency the company pays

Paid for 9 years. Last went ex-dividend on 17 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.1390.1350.2710.160.150.120.110.13

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.